Full-Time

Contracts Administration & Technology Specialist

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$117k - $131kAnnually

Senior

San Carlos, CA, USA

Hybrid position.

Category
Contract Management
Legal & Compliance
Required Skills
NetSuite
Requirements
  • B.A./B.S.; 5+ years experience in contracts administration and legal operations; paralegal or JD with contracts administration experience welcome and encouraged.
  • Experience working with Ironclad required.
  • Understanding of purchasing system/procurement tools such as NetSuite required.
  • Light coding or similar experience/background desired.
  • Understanding of the technology industry, including software development, IT services, and related technical terminology.
  • Ability to comprehend and interpret technical specifications and requirements.
  • Strong interpersonal skills with the ability to collaborate with colleagues. Excellent written and verbal communication skills.
  • Strong attention to detail, excellent organization skills and the highest standards for accuracy and precision.
  • Demonstrated problem solver with a systems-thinking mindset.
  • Pro-active and self-motivated with a customer service orientation and a commitment to delivering high quality support.
  • Strong computer skills with Microsoft Office 365 (Outlook mail, Word processing, Excel, Zoom meetings); redlining experience through tool such as Litera/Workshare (or Word).
  • Passion to learn, proactive, high integrity, and strong work ethic.
  • Experience in biotech/pharma industry is preferred but not required.
  • Models our Core Values: is experienced as someone who exemplifies the culture we want to create; operates with transparency; is trusted.
Responsibilities
  • Responsible for the oversight and management of Vaxcyte’s contract management system, Ironclad.
  • Oversee legal agreement intake as needed, including preliminary review and saving to contract repository. This will include redlining and cleaning of documents for signature; coordination of signatures, approvals, vendor and internal requestor outreach, and finalization/saving of agreements to ensure version control and accurate document retention.
  • Will work in leading the optimization and improvement of the legal contract repository and organization of all legal documents.
  • Will collaborate with attorneys and consultants to develop and consistently update Ironclad workflows and use cases.
  • Will be responsible for guiding and educating internal users on the functionality of Ironclad and the various workflows.
  • Responsible for making and tracking updates within Ironclad and keeping the contracts team updated as appropriate.
  • Manage Ironclad licenses and permissions and track licenses and fees.
  • Create Insight reports and expand upon use of reporting data from Ironclad.
  • Manage and drive varied ad hoc legal and cross functional team projects.
  • Support for assessment and implementation of AI.
  • Assist with compliance activities and work closely with procurement and finance teams.
  • Provide administrative support to the Legal Department as needed.
  • Collaborate with the attorneys to revise materials from outside counsel.
  • Prepare/update presentations for the legal team, primarily contracts group.
  • Experience in building relationships with cross functional teams and key internal and external stakeholders to achieve Legal team and company goals.
  • Patience with internal client/customers.
  • Demonstrated problem solving abilities and strong organizational skills.
  • Must be self-motivating, extremely proactive, prioritize and manage work, and show attention to detail.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA for adult use. Vaxcyte employs advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while eliciting a strong immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial infections on global health.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

23%

1 year growth

61%

2 year growth

132%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
  • The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
  • The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.

What critics are saying

  • The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
  • The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.

What makes Vaxcyte unique

  • Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
  • Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
  • The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.

Help us improve and share your feedback! Did you find this helpful?